227 related articles for article (PubMed ID: 16180235)
41. Bigh3 silencing increases retinoblastoma tumor growth in the murine SV40-TAg-Rb model.
Allaman-Pillet N; Oberson A; Schorderet DF
Oncotarget; 2017 Feb; 8(9):15490-15506. PubMed ID: 28099942
[TBL] [Abstract][Full Text] [Related]
42. Aberrant expression of HOXA9, DEK, CBL and CSF1R in acute myeloid leukemia.
Casas S; Nagy B; Elonen E; Aventín A; Larramendy ML; Sierra J; Ruutu T; Knuutila S
Leuk Lymphoma; 2003 Nov; 44(11):1935-41. PubMed ID: 14738146
[TBL] [Abstract][Full Text] [Related]
43. MicroRNA-125b suppresses the development of bladder cancer by targeting E2F3.
Huang L; Luo J; Cai Q; Pan Q; Zeng H; Guo Z; Dong W; Huang J; Lin T
Int J Cancer; 2011 Apr; 128(8):1758-69. PubMed ID: 20549700
[TBL] [Abstract][Full Text] [Related]
44. Expression of p14ARF, MDM2, and MDM4 in human retinoblastoma.
Guo Y; Pajovic S; Gallie BL
Biochem Biophys Res Commun; 2008 Oct; 375(1):1-5. PubMed ID: 18644346
[TBL] [Abstract][Full Text] [Related]
45. Expression of retina-specific genes by mouse retinoblastoma cells.
Bernstein SL; Kutty G; Wiggert B; Albert DM; Nickerson JM
Invest Ophthalmol Vis Sci; 1994 Oct; 35(11):3931-7. PubMed ID: 7928191
[TBL] [Abstract][Full Text] [Related]
46.
Panagopoulos I; Gorunova L; Torkildsen S; Tjønnfjord GE; Micci F; Heim S
Cancer Genomics Proteomics; 2017; 14(6):437-443. PubMed ID: 29109093
[TBL] [Abstract][Full Text] [Related]
47. Apoptosis inhibition by the human DEK oncoprotein involves interference with p53 functions.
Wise-Draper TM; Allen HV; Jones EE; Habash KB; Matsuo H; Wells SI
Mol Cell Biol; 2006 Oct; 26(20):7506-19. PubMed ID: 16894028
[TBL] [Abstract][Full Text] [Related]
48. DEK Expression is controlled by E2F and deregulated in diverse tumor types.
Carro MS; Spiga FM; Quarto M; Di Ninni V; Volorio S; Alcalay M; Müller H
Cell Cycle; 2006 Jun; 5(11):1202-7. PubMed ID: 16721057
[TBL] [Abstract][Full Text] [Related]
49. Seed-targeting anti-miR-21 inhibiting malignant progression of retinoblastoma and analysis of their phosphorylation signaling pathways.
Ding Y; Wu M; Liu J; Wu C; Huang R; Zhu R; Fei J
Exp Eye Res; 2014 May; 122():1-8. PubMed ID: 24607444
[TBL] [Abstract][Full Text] [Related]
50. A novel LncRNA transcript, RBAT1, accelerates tumorigenesis through interacting with HNRNPL and cis-activating E2F3.
He X; Chai P; Li F; Zhang L; Zhou C; Yuan X; Li Y; Yang J; Luo Y; Ge S; Zhang H; Jia R; Fan X
Mol Cancer; 2020 Jul; 19(1):115. PubMed ID: 32669100
[TBL] [Abstract][Full Text] [Related]
51. E2F3 amplification and overexpression is associated with invasive tumor growth and rapid tumor cell proliferation in urinary bladder cancer.
Oeggerli M; Tomovska S; Schraml P; Calvano-Forte D; Schafroth S; Simon R; Gasser T; Mihatsch MJ; Sauter G
Oncogene; 2004 Jul; 23(33):5616-23. PubMed ID: 15122326
[TBL] [Abstract][Full Text] [Related]
52. 6p abnormalities and TNF-alpha over-expression in retinoblastoma cell line.
Imbert I; Coignet LJ; Pellestor F
Cancer Genet Cytogenet; 2001 Jul; 128(2):141-7. PubMed ID: 11463453
[TBL] [Abstract][Full Text] [Related]
53. Tiling resolution array CGH and high density expression profiling of urothelial carcinomas delineate genomic amplicons and candidate target genes specific for advanced tumors.
Heidenblad M; Lindgren D; Jonson T; Liedberg F; Veerla S; Chebil G; Gudjonsson S; Borg A; Månsson W; Höglund M
BMC Med Genomics; 2008 Jan; 1():3. PubMed ID: 18237450
[TBL] [Abstract][Full Text] [Related]
54. Differentially expressed miRNAs in retinoblastoma.
Martin J; Bryar P; Mets M; Weinstein J; Jones A; Martin A; Vanin EF; Scholtens D; Costa FF; Soares MB; Laurie NA
Gene; 2013 Jan; 512(2):294-9. PubMed ID: 23103829
[TBL] [Abstract][Full Text] [Related]
55. Melanoma proliferation and chemoresistance controlled by the DEK oncogene.
Khodadoust MS; Verhaegen M; Kappes F; Riveiro-Falkenbach E; Cigudosa JC; Kim DS; Chinnaiyan AM; Markovitz DM; Soengas MS
Cancer Res; 2009 Aug; 69(16):6405-13. PubMed ID: 19679545
[TBL] [Abstract][Full Text] [Related]
56. Promotion of cell proliferation by the proto-oncogene DEK enhances oral squamous cell carcinogenesis through field cancerization.
Nakashima T; Tomita H; Hirata A; Ishida K; Hisamatsu K; Hatano Y; Kanayama T; Niwa A; Noguchi K; Kato K; Miyazaki T; Tanaka T; Shibata T; Hara A
Cancer Med; 2017 Oct; 6(10):2424-2439. PubMed ID: 28834425
[TBL] [Abstract][Full Text] [Related]
57. The DEK oncoprotein and its emerging roles in gene regulation.
Sandén C; Gullberg U
Leukemia; 2015 Aug; 29(8):1632-6. PubMed ID: 25765544
[TBL] [Abstract][Full Text] [Related]
58. Pax6 regulation in retinal cells by CCCTC binding factor.
Li T; Lu Z; Lu L
Invest Ophthalmol Vis Sci; 2006 Dec; 47(12):5218-26. PubMed ID: 17122106
[TBL] [Abstract][Full Text] [Related]
59. [Relationship between DEK oncogene expression and oral squamous cell carcinoma].
Wang X; Huang SH; Yu LQ; Liu J; Diao Y; Sun CF
Shanghai Kou Qiang Yi Xue; 2014 Feb; 23(1):75-9. PubMed ID: 24608617
[TBL] [Abstract][Full Text] [Related]
60. SiRNA knockdown of the DEK nuclear protein mRNA enhances apoptosis and chemosensitivity of canine transitional cell carcinoma cells.
Yamazaki H; Iwano T; Otsuka S; Kagawa Y; Hoshino Y; Hosoya K; Okumura M; Takagi S
Vet J; 2015 Apr; 204(1):60-5. PubMed ID: 25773167
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
